• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Dova Pharmaceuticals













Interesting that the only people who seem to acknowledge that this is rare disease are the people on this thread. Our leadership doesn’t!!

Our big pharma managers are all butt because our CEO acknowledged what the salesforce said regarding this being a big pharma disaster. It’s way too big pharma here.

And our BMS sales director changed the IC plan based on what? It still sucks! When have you ever seen a sales force not make money during a launch?
 








Interesting that the only people who seem to acknowledge that this is rare disease are the people on this thread. Our leadership doesn’t!!

Our big pharma managers are all butt because our CEO acknowledged what the salesforce said regarding this being a big pharma disaster. It’s way too big pharma here.

And our BMS sales director changed the IC plan based on what? It still sucks! When have you ever seen a sales force not make money during a launch?
When the launch fails because of a bad drug and/or inept sales team (led by inept upper management)
Asked and answered
 




Interesting that the only people who seem to acknowledge that this is rare disease are the people on this thread. Our leadership doesn’t!!

Our big pharma managers are all butt because our CEO acknowledged what the salesforce said regarding this being a big pharma disaster. It’s way too big pharma here.

And our BMS sales director changed the IC plan based on what? It still sucks! When have you ever seen a sales force not make money during a launch?


Unfortunately, this company is going to fail if they start losing people. No one from upper management had startup experience and most were big pharma their entire careers. NSM isn’t the sharpest tool in the shed and the IC plan is based on what? Certainly no rare diseas. No one wants to look at the elephant in the room.
 




Unfortunately, this company is going to fail if they start losing people. No one from upper management had startup experience and most were big pharma their entire careers. NSM isn’t the sharpest tool in the shed and the IC plan is based on what? Certainly no rare diseas. No one wants to look at the elephant in the room.
BN has his suck up managers and suck up reps he brought over from BMS. Def plays favorites.
 








BN has his suck up managers and suck up reps he brought over from BMS. Def plays favorites.

Agreed. Alex doesn’t seem to have any idea what is happening. BN, his managers and LJ are all big pharma. No idea how start up works or what’s needed to make this work. How long do they expect people to stay?
 








Didn’t you all see this prior too and in the interviews??
Take the time to READ people’s background’s!! (Or lack there of)
If your shocked, it’s truly all on you!!
Research goes way beyond looking at the company website people!
 








Didn’t you all see this prior too and in the interviews??
Take the time to READ people’s background’s!! (Or lack there of)
If your shocked, it’s truly all on you!!
Research goes way beyond looking at the company website people!

And what information, pray tell, was available on the website (or anywhere) that would have helped us predict this? The Dova website references rare disease. Leadership doesn’t. The big pharma mentality that is slowly killing this company was not predictable. Dova touts rare disease, but you can’t have success in rare disease with big pharma mentality. Call volumes, excessive ride alongs, goals based on what exactly? One rep already left because of it. She won’t be the last of this doesn’t change quickly.
 




And what information, pray tell, was available on the website (or anywhere) that would have helped us predict this? The Dova website references rare disease. Leadership doesn’t. The big pharma mentality that is slowly killing this company was not predictable. Dova touts rare disease, but you can’t have success in rare disease with big pharma mentality. Call volumes, excessive ride alongs, goals based on what exactly? One rep already left because of it. She won’t be the last of this doesn’t change quickly.


Well you could have looked on LinkedIn at your interviewer and the nsm at the least.
 








I love reading Café Pharma - it never disappoints! I am reminded that certain people love to complain behind anonymity. I really hope he/she is polishing his/her resume so they can move to the next company and do the same thing. The same people are always part of their self created problems. C'est la vie!
 




I love reading Café Pharma - it never disappoints! I am reminded that certain people love to complain behind anonymity. I really hope he/she is polishing his/her resume so they can move to the next company and do the same thing. The same people are always part of their self created problems. C'est la vie!

Nailed it!
 




I love reading Café Pharma - it never disappoints! I am reminded that certain people love to complain behind anonymity. I really hope he/she is polishing his/her resume so they can move to the next company and do the same thing. The same people are always part of their self created problems. C'est la vie!

Like yourself ?
 




What info??? Your not serious??
Try listening to the hacks that we’re interviewing you!!

Didn’t you at least view their profiles? Or did posting your Cats favorite Halloween costume for Halloween on Facebook take up the hour prior to your interview?

NSD was a career big Pharma guy with long time employment at 1 company I might add (again, that took 4 seconds to read on LinkedIn)

My interviewers were absolutely clueless when I talked about the Rare Disease environment.....

And what information, pray tell, was available on the website (or anywhere) that would have helped us predict this? The Dova website references rare disease. Leadership doesn’t. The big pharma mentality that is slowly killing this company was not predictable. Dova touts rare disease, but you can’t have success in rare disease with big pharma mentality. Call volumes, excessive ride alongs, goals based on what exactly? One rep already left because of it. She won’t be the last of this doesn’t change quickly.